MDGL FY 2020 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$471,000

Operating Income

-$206M

Net Income

-$202M

EPS (Diluted)

$-13.09

Cash Flow

Operating Cash Flow

-$158M

Free Cash Flow

-$158M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$287M

Total Liabilities

$47M

Stockholders' Equity

$240M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$471,000	-$112,000	-320.5%
Operating Income	-$206M	-$95M	-117.2%
Net Income	-$202M	-$84M	-140.9%